Protocol Design Optimization Is Starting to Improve Clinical Study Performance, According to the Tufts Center for the Study of Drug Development
September 09, 2014 09:00 ET
|
Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwired - Sep 9, 2014) - Efforts by drug companies to streamline and improve the execution of clinical study designs -- to counter mounting costs and shorten development times...
Drug Company Collaborations to Reduce Development Risk Are Increasing, According to Tufts Center for the Study of Drug Development
August 07, 2014 09:00 ET
|
Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwired - Aug 7, 2014) - As pharmaceutical and biotech companies look to speed development, lower cost, and reduce technical risks associated with new drug development, they are...
Orphan Drug Approvals Have Increased, But High Costs Pose Challenges for Patients, According to the Tufts Center for the Study of Drug Development
July 10, 2014 09:00 ET
|
Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwired - Jul 10, 2014) - Although the pace of approvals for new orphan drugs -- medicines that treat relatively rare conditions -- have increased in the United States and Europe...
Mobile Health Devices Market to Grow 8-Fold to $41.8 Billion in 2023
July 01, 2014 07:30 ET
|
Lux Research
BOSTON, MA--(Marketwired - Jul 1, 2014) - Driven by adoption of vital signs monitoring and in vitro diagnostic (IVD) devices, the mobile health (mHealth) market will grow eight-fold from $5.1...
Risk-Sharing Drug Development Programs Experience Longer Development Times, According to the Tufts Center for the Study of Drug Development
May 08, 2014 09:00 ET
|
Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwired - May 8, 2014) - Drug development programs that involve several partners who share clinical development risks accounted for about half of all new therapeutic drug approvals...
C3 Jian Closes $60M Series D Financing
March 17, 2014 15:12 ET
|
C3 Jian, Inc.
LOS ANGELES, March 17, 2014 (GLOBE NEWSWIRE) -- C3 Jian, Inc., a private company focused on developing proprietary drugs with an initial focus on improving oral healthcare, announced today the close...
C3 Jian Initiates Phase 2 Clinical Trial of Anti-Cavity Drug
March 07, 2014 18:40 ET
|
C3 Jian, Inc.
LOS ANGELES, March 7, 2014 (GLOBE NEWSWIRE) -- C3 Jian, Inc., a private company focused on providing improved oral healthcare, announced today that the first Phase 2 Clinical Trial for its novel drug,...
Drug Developers Circumspect About Using Social Media in Clinical Research, According to the Tufts Center for the Study of Drug Development
March 06, 2014 09:00 ET
|
Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwired - Mar 6, 2014) - Social media is gaining ground as an important tool to improve the clinical research process through more effective engagement of patient communities, but...
Hearst Corporation Announces Formation of Hearst Health
January 27, 2014 08:53 ET
|
Hearst Corporation
NEW YORK, NY--(Marketwired - Jan 27, 2014) - Hearst Corporation today announced the creation of Hearst Health, a new brand that encompasses its healthcare information businesses, giving the company...
Matrix Medical Network Changing Lives at Record Pace
January 24, 2014 13:14 ET
|
Matrix Medical Network
SCOTTSDALE, Ariz., Jan. 24, 2014 (GLOBE NEWSWIRE) -- Matrix Medical Network, a national leader in providing prospective health assessment services for Medicare Advantage (MA) plan members, today...